Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2015; 21(43): 12510-12512
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12510
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12510
Hepatitis C eradication: A long way to go
Yasir Waheed, Foundation University Medical College, Foundation University Islamabad, Islamabad 46000, Pakistan
Author contributions: Waheed Y solely contributed to the article.
Conflict-of-interest statement: No conflict of interest declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yasir Waheed, PhD, Foundation University Medical College, Foundation University Islamabad, DHA Phase I, Islamabad 46000, Pakistan. yasir_waheed_199@hotmail.com
Telephone: +92-300-5338171
Received: June 4, 2015
Peer-review started: June 6, 2015
First decision: July 10, 2015
Revised: July 28, 2015
Accepted: September 14, 2015
Article in press: September 15, 2015
Published online: November 21, 2015
Peer-review started: June 6, 2015
First decision: July 10, 2015
Revised: July 28, 2015
Accepted: September 14, 2015
Article in press: September 15, 2015
Published online: November 21, 2015
Core Tip
Core tip: With the availability of new direct-acting antivirals for hepatitis C virus (HCV), some people think that eradication of HCV may be only one step away. There are a number of issues that need to be overcome to win the fight against HCV. Although the cost of HCV treatment is reduced for certain countries, cost remains a big problem for low and middle income countries for the treatment of a large number of patients. In low income countries, 47% of blood transfusions are from laboratories with no quality management in place. There is a lack of knowledge and awareness about HCV among healthcare providers, policy makers, general public, and at risk populations.